Autopsy report · NCT02510560
Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants
Cause of deathFunding or business
“Sponsor decision”
Life of this trial
- Registered 1 year 3 months before it started.
- Ran for about 1 year 7 months before it stopped.
- 300 participants enrolled.
- Results were posted on the registry 7 years 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Elgan Pharma Ltd.
- Sponsor type
- Industry
- Conditions
- Premature Birth of Newborn; Intestinal Malabsorption
- Interventions
- NTRA-2112; Placebo
- Participants
- 300
- Sites
- 50
- Countries
- Belgium, France, Germany, Hungary, Israel, Italy, Netherlands, Spain, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.